CAR-T cells: the narrow path between hope and bankruptcy?-Reference-Cited by-同舟云学术

CAR-T cells: the narrow path between hope and bankruptcy?

Published:2017-12 Issue:12 Volume:52 Page:1588-1589
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Chabannon C^ORCID, ,Kuball J,Mcgrath E^ORCID,Bader P,Dufour C,Lankester A,Basak G W,Montoto S,Nagler A,Snowden J A,Styczynski J,Duarte R F,Kröger N,Mohty M

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2017241.pdf

Reference17 articles.

1. Roselli EA, Mezzadra R, Frittoli MC, Maruggi G, Biral E, Mavilio F et al. Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med 2010; 2: 315–328.

2. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507–1517.

3. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33: 540–549.

4. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517–528.

5. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7: 303ra139.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies;Best Practice & Research Clinical Haematology;2024-06

2. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma;Journal of Clinical Oncology;2024-05-10

3. Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review;Current Drug Research Reviews;2023-11

4. Challenges and solutions to cancer-related financial toxicity according to Australian health professionals: qualitative results from a national survey;Supportive Care in Cancer;2023-07

5. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper;The Lancet Haematology;2022-10